[ALIM] Alimera Sciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.12 Change: 0.05 (4.67%)
Ext. hours: Change: 0 (0%)

chart ALIM

Refresh chart

Strongest Trends Summary For ALIM

ALIM is in the long-term down -88% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company?s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient?s eye to a placement site that uses the eye?s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dain

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.5 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 79.82% Sales Growth - Q/Q126.19% P/E-2.68
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.76% ROE-61.48% ROI-29.4%
Current Ratio5.86 Quick Ratio5.69 Long Term Debt/Equity0.74 Debt Ratio0.3
Gross Margin88.7% Operating Margin-355.13% Net Profit Margin-242.72% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-200 K Cash From Investing Activities-160 K Cash From Operating Activities-14.7 M Gross Profit3.65 M
Net Profit-9.79 M Operating Profit-10.99 M Total Assets96.83 M Total Current Assets70.31 M
Total Current Liabilities11.99 M Total Debt34.53 M Total Liabilities56.26 M Total Revenue3.94 M
Technical Data
High 52 week1.3 Low 52 week0.75 Last close0.91 Last change2.55%
RSI34.87 Average true range0.05 Beta0.9 Volume265.7 K
Simple moving average 20 days-2.23% Simple moving average 50 days-9.84% Simple moving average 200 days-7.95%
Performance Data
Performance Week-3.2% Performance Month-5.09% Performance Quart-7.16% Performance Half-18.03%
Performance Year-23.54% Performance Year-to-date-1.12% Volatility daily3.57% Volatility weekly7.99%
Volatility monthly16.37% Volatility yearly56.69% Relative Volume294.18% Average Volume107.21 K
New High New Low

News

2019-11-14 12:45:00 | Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

2019-11-13 08:00:00 | Alimera Sciences Terminates Equity Purchase Agreement

2019-11-08 08:14:09 | The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

2019-11-07 18:00:00 | Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

2019-11-05 08:30:00 | Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

2019-11-05 05:06:39 | One Thing To Remember About The Alimera Sciences, Inc. NASDAQ:ALIM Share Price

2019-10-29 16:42:38 | Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

2019-10-29 07:32:34 | The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

2019-10-25 08:30:05 | Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

2019-10-23 08:30:05 | Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

2019-10-03 08:30:00 | Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

2019-10-02 08:00:00 | Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

2019-10-01 08:00:00 | Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

2019-09-12 08:00:00 | Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

2019-09-05 08:00:00 | Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

2019-09-03 08:00:00 | Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

2019-08-06 07:24:36 | How Much Of Alimera Sciences, Inc. NASDAQ:ALIM Do Institutions Own?

2019-08-05 08:00:00 | Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

2019-07-31 18:06:42 | Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT

2019-07-29 18:51:28 | Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-23 08:00:00 | Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting

2019-07-22 08:00:00 | Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update

2019-07-19 08:00:00 | Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors

2019-06-20 09:12:06 | Did Changing Sentiment Drive Alimera Sciences's NASDAQ:ALIM Share Price Down A Painful 85%?

2019-06-20 08:00:00 | Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis

2019-06-06 08:00:00 | Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment

2019-06-04 05:34:09 | Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?

2019-05-22 08:00:00 | Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®

2019-05-21 08:24:12 | Top Ranked Momentum Stocks to Buy for May 21st

2019-05-14 08:05:00 | Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

2019-05-01 17:18:10 | Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT

2019-04-29 16:15:00 | Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview

2019-04-23 16:30:00 | Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update

2019-04-23 08:30:00 | Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIENR to be Presented at the Association for Research and Vision in Ophthalmology ARVO Annual Meeting

2019-04-04 08:00:00 | Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer

2019-03-25 09:28:00 | Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIENR in Europe

2019-03-21 08:00:00 | Alimera Sciences Announces Approval for ILUVIEN R in Kuwait

2019-03-06 08:00:00 | Alimera Sciences Announces the Reimbursement of ILUVIENR in France

2019-02-20 10:31:03 | Will Alimera Sciences ALIM Report Negative Q4 Earnings? What You Should Know

2019-02-19 15:26:22 | Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT

2019-02-19 07:00:00 | Alimera Sciences, Inc. to Host Earnings Call

2019-02-18 16:15:00 | Alimera Sciences Reports Record Fourth Quarter and 2018 Results

2019-02-05 07:30:00 | Alimera Sciences Announces Approval for ILUVIENR in Lebanon

2019-02-04 07:30:00 | Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019

2019-01-30 11:07:20 | Eye implant is helping treat vision loss in diabetics

2019-01-07 06:30:00 | Alimera Sciences Affirms Record 2018 Revenues

2018-12-21 11:36:47 | What Type Of Shareholder Owns Alimera Sciences, Inc.’s NASDAQ:ALIM?

2018-12-17 07:00:00 | Alimera Sciences Announces Pricing Approval For ILUVIENR in the U.A.E.

2018-11-29 07:15:00 | Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer

2018-11-26 15:30:00 | Alimera Sciences Announces Canadian Regulatory Approval for ILUVIENR